From: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Trial (number of patients) | Agent tested | Entry criteria | Primary endpoints |
---|---|---|---|
PURSUIT (10,948) | Eptifibatide | CP at rest or minimal exertion within | Death, and non-fatal MI, at 30 days |
 |  | 24 hours and either ischemic ECG |  |
 |  | changes* or CK-MB elevations |  |
PRISM-PLUS (1915) | Tirofiban | CP at rest or minimal exertion within | Death, MI, or refractory ischemia, at 7 days |
 |  | 12 hours and either ischemic ECG |  |
 |  | changes* or CK-MB elevations |  |
PRISM (3232) | Tirofiban | CP at rest or minimal exertion within | Death, MI or refractory ischemia, at 48 hours |
 |  | 24 hours and ischemic ECG changes* |  |
 |  | or CK-MB elevations or history of CAD or |  |
 |  | positive stress test |  |
PARAGON A (2282) | Lamifiban | CP at rest within 12 hours and ischemic | Death, and non-fatal MI, at 30 days |
 |  | ECG changes* |  |
PARAGON B (5225) | Lamifiban | Patients within 12 hours of symptoms of | The composite incidence of death, MI, or SRI, at |
 |  | acute myocardial ischemia and ECG changes* | 30 days |
GUSTO IV-ACS (7800) | Abciximab | ACS within last 24 hours; > 5 min anginal | All-cause mortality, composite endpoint of death, |
 |  | symptoms at rest, and either + troponin I/T, | or MI, at 30 days |
 |  | or ST depression ≥ 0.5 mm |  |